Pharmaceuticals
Price
$263.04
+3.57%Market Cap
$633.19B
Day High
$263.10
Day Low
$254.00
JNJ delivered strong Q1 FY2026 revenue growth of 9.9% to $24.1B, but net income fell 52.4% to $5.2B, likely driven by elevated SG&A (+18.0%) and one-time charges, while cash and equivalents dropped sharply by 43.6%.
Key risk: Litigation and Legal Settlement Risk
The dramatic 52.4% decline in net income despite strong revenue growth strongly implies significant litigation-related charges or settlement payments in Q1 FY2026. JNJ has historically faced large-scale litigation (e.g., talc-related lawsuits), and ongoing legal proceedings could continue to weigh heavily on earnings and cash flows.
Other Pharmaceuticals companies